Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository

Hidradenitis Suppurativa Clinical Trial

— HS PROGRESS  

Official title:

Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04115566
• Other study ID #: 18-27002
• Status: Recruiting
• Start date: August 1, 2020
• Est. completion date: September 1, 2029

Study information

• Verified date: July 2023
• Source: University of California, San Francisco
• Contact: Hannah Balter
• Phone: 415-502-4741
• Email: hannah.balter[@]ucsf.edu
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characterize the clinical and biological features of HS. The results of this research will provide a basis for the development of an HS clinical classification system and identification of potential treatments for HS.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3000
• Est. completion date: September 1, 2029
• Est. primary completion date: September 1, 2029
• Gender: All
• Age group: 10 Years and older

Eligibility

Inclusion Criteria:

1. Male or female = 10 years of age

2. Diagnosis of HS by a dermatologist or practitioner experienced in making a diagnosis of HS

3. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.

Exclusion Criteria:

1. Inability to give informed consent or unavailability of a parent/guardian who is able and willing to give informed consent.

Related Conditions & MeSH terms

• Hidradenitis
• Hidradenitis Suppurativa

Locations

Country	Name	City	State
United States	University of California San Francisco	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Objective	The primary aim of this study is to identify clinical and biologic characteristics of hidradenitis suppurativa.	2019-2029
Secondary	Secondary Objective	Secondary aims include correlating alterations in clinical and biological characteristics with disease status, and identifying genetic variants that predict disease progression or response to therapy.	2019-2029